Keeping Track Of Breakthrough Therapy Designations: Depression, Headaches, Hepatitis

The latest developments in one of the US FDA's favorite pathways.

Sparks

Some sponsors are enjoying an extra serving of regulatory cranberry sauce this week after their development programs received a breakthrough therapy designation (BTD) from the US FDA.

COMPASS Pathways announced a breakthrough therapy designation Oct. 23 for its treatment-resistant depression candidate psilocybin, reflecting a growing trend of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards